#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

Episode 409

0:00-2:26:26
76%

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Lloyd B. Klickstein is a physician-scientist who has spent more than 20 years at the intersection of drug discovery, healthy aging, and preventive medicine. Drawing on his experience in academic medicine, translational research, and biotechnology, Lloyd walks through the full arc of modern drug development. He explains how scientists identify an unmet medical need and decide which diseases and therapeutic targets are worth pursuing. From there, he takes us through the process of engineering a drug, testing it in animals, and navigating clinical trials and regulatory approval. Using bimagrumab as a case study, Lloyd explains the rationale for targeting myostatin and activin signaling to increase muscle mass and strength and describes how the antibody was engineered and screened. He then walks through what was learned from early clinical trials. Unexpected effects on fat mass and type 2 diabetes helped reshape bimagrumab's development as a potential treatment for obesity, including its use in combination with semaglutide. Along the way, Peter and Lloyd explore the differences among drug modalities, including biologics and small-molecule therapeutics. They discuss the roles of patents and capital allocation in drug development, along with the requirements for IND submission and GMP manufacturing.

Publisher

The Peter Attia Drive

Link

peterattiamd.com/lloydklickstein2/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260928-pod-lloydklickstein2&utm_content=260928-pod-lloydklickstein2-podfeed

Published

September 28, 2026

Duration

2h 26m

Format

Podcast

Category

Lifestyle · Health & Wellness

Source

RSS feed

Host

Peter Attia, MD

TP

The Peter Attia Drive

@peterattiadrive

#moderndrugdevelopment #regulatoryhurdles #lloydklickstein

The Nile